The Alzheimer’s Disease Therapeutics and Diagnostics Market reached $6.71bn in 2016. The Alzheimer’s Disease Therapeutics and Diagnostics Market is expected to grow at a CAGR of 15.3% in the second half of the forecast period.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 207-page report you will receive 73 tables and 76 figures– all unavailable elsewhere.
The 207-page report provides clear detailed insight into the Alzheimer’s Disease Therapeutics and Diagnostics Market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Alzheimer’s Disease Market forecasts from 2017-2027, further broken down into:
– Alzheimer’s Drugs Market
– Alzheimer’s Diagnostics Market
• Quantitative analysis of the Alzheimer’s drug market from 2017 to 2027. It includes analysis and forecast of top drugs and pipeline drugs in the market:
– Namenda
– Aricept
– Exelon
– Solanezumab
– Gantenerumab
– Verubecestat
• Quantitative analysis of the Alzheimer’s diagnostics market from 2017 to 2027. In includes the guidelines and recent research and development in the field of diagnosis. There is further analysis and forecast provided for subsectors of Alzheimer’s diagnosis from 2017to 2027:
– Diagnostic biomarker market
– Others
• Profiles of leading pharma companies involved in developing Alzheimer’s drugs globally. It contains overviews of the companies’ segments, recent mergers and acquisitions and analysis of the companies’ recent financial performances. It also includes the details of the drugs for Alzheimer’s in the pipeline and forecast of the company drugs available in the market:
– Pfizer
– Eisai
– Actavis
– Lundbeck
– Daiichi Sankyo
– Novartis
– TauRx
– vTv Therapeutics
• Profiles of leading companies developing diagnostics tests for Alzheimer’s disease:
– Eli Lilly
– Amarantus Biosciences Holdings
– Piramal Enterprises
– GE Healthcare
– Navidea
– DiaGenic
• This report also breaks down the revenue forecast for the Alzheimer’s Disease Market by national market:
– US
– Germany
– France
– Italy
– Spain
– UK
– Japan
– China
– Brazil
– India
– Russia
• This report covers the qualitative analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market. It includes SWOT analysis: Strengths, Weaknesses, Opportunities and Threats of the market.
• This report shows transcripts of research interviews conducted by Visiongain:
– David Hung, Chief Executive Officer of Axovant Sciences Inc.
– Dr. Gill Farrar, PET Neurology, Scientific Director at GE Healthcare
– Phyllis Ferrell, Vice President and Alzheimer’s Disease Global Platform Leader at Eli Lilly and Co.
Buy our report today Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027: Leading Drugs, Pipeline Drugs, Biomarkers, Leading Companies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market Overview
1.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Alzheimer’s Disease: An Introduction
2.1 Neurodegenerative Diseases
2.1.1 What is Alzheimer’s Disease?
2.1.2 What Causes Alzheimer’s Disease?
2.1.2.1 Alzheimer’s Disease: Type 3 Diabetes?
2.1.3 Management of Alzheimer’s Disease
2.1.4 The Socio-Economic Impact of Alzheimer’s Disease
2.1.5 Diagnosis of Alzheimer’s Disease
3. Alzheimer’s Disease Therapeutics and Diagnostics Market 2017-2027
3.1 Alzheimer’s Disease Therapeutics and Diagnostics Market, 2017
3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
3.2.1 The Market Has Been Left Exposed to Intensified Generic Competition
3.2.2 Healthcare Costs for Alzheimer’s Disease Will Surpass All Other Medical Expenses
3.2.3 New Diagnostics and Drugs Regulatory Guidelines Will Lower the Barriers to Entry
3.3 Drivers and Restraints
3.4 Shift in Focus to Early Disease Stages
4. The Alzheimer’s Disease Drugs Market, 2017-2027
4.1 Current Approaches and Unmet Needs in the Treatment of Alzheimer’s disease
4.2 The Alzheimer’s Disease Drugs Market, 2016
4.3 Changing Market Shares of the Leading Alzheimer’s Disease Drugs, 2017-2027
4.4 The Alzheimer’s Disease Drugs Market Forecast 2017-2027
4.5 Namenda – Forest Laboratories, Subsidiary of Allergan
4.5.1 Namenda Sales Forecast, 2017-2027
4.6 Aricept
4.6.1 Aricept Sales Forecast, 2017-2027
4.7 Exelon
4.7.1 Exelon Sales Forecast, 2017-2027
4.8 Alzheimer’s Disease Drugs Pipeline, 2017
4.8.1 New Guidelines: FDA to Relax Rules for the Approval of Alzheimer’s Drugs and EMA published new draft guidance for AD treatments
4.8.2 Will Novel Drug Development Strategies Prove Successful?
4.8.3 Solanezumab (Eli Lilly)
4.8.3.1 Solanezumab Sales Forecast 2017-2027
4.8.4 Gantenerumab (Roche)
4.8.4.1 Gantenerumab Pipeline Forecast, 2016-2027
4.8.5 Verubecestat MK-8931 (Merck)
4.8.5.1 Verubecestat MK-8931 Pipeline Forecast, 2016-2027
4.8.6 Idalopirdine Lu AE58054 (Lundbeck)
4.8.7 Azeliragon TTP488 (TransTechPharma)
4.8.8 LMTX (TauRx)
4.8.9 Encenicline EVP-6124 (Forum Pharmaceuticals)
4.8.10 Axona (Accera)
4.8.11 AD-4833 (Takeda Pharmaceuticals)
4.8.12 Intepirdine RVT-101 (Axovant Sciences Ltd)
4.9 Deep Brain Stimulation (Functional Neuromodulation)
4.10 Recent Research on Alzheimer’s Disease
5. Leading Companies in the Alzheimer’s Disease Drugs Market, 2017
5.1 Pfizer, Inc
5.1.1 Sales and Recent Performance Analysis, 2016
5.1.2 Pfizer: Aricept
5.1.3 Pfizer: R&D Capabilities and Alzheimer’s Disease Drug Candidates
5.2 Eisai
5.2.1 Sales and Recent Performance Analysis, 2016
5.2.2 Eisai: Aricept
5.2.3 Eisai: R&D Capabilities and Alzheimer’s Disease Drug Candidates
5.2.4 Collaboration with Biogen
5.2.5 Partnership with GE Healthcare for Diagnostic Development
5.3 Forest Laboratories (Acquired by Allergan)
5.3.1 Acquisition by Allergan
5.3.2 Forest: Namenda
5.3.3 Namenda’s Sales and Recent Performance Analysis, 2016
5.4 Lundbeck A/S
5.4.1 Sales and Recent Performance Analysis, 2016
5.4.2 Lundbeck: R&D Capabilities
5.4.3 Lundbeck’s Alzheimer’s Disease Drug Pipeline
5.4.4 Lundbeck: Ebixa
5.5 Daiichi Sankyo
5.5.1 Financial Sales and Recent Performance, 2016
5.5.2 Daiichi Sankyo: Memary
5.6 Novartis AG
5.6.1 Sales and Recent Performance Analysis
5.6.2 Novartis: Exelon
5.6.3 eHealth Programme Delivering Innovation
5.6.4 Novartis: Alzheimer’s Disease Drug Pipeline
5.7 TauRx
5.7.1 Partnership with Bayer Schering Pharma AG
5.8 vTv Therapeutics
5.8.1 TTP Translational Technology
5.8.2 vTv Therapeutics: Alzheimer’s Disease Pipeline Portfolio
6. The Alzheimer’s Disease Diagnostics Market, 2016-2027
6.1 There is Still a Strong Market Need for Effective Diagnosis
6.2 The Alzheimer’s Disease Diagnostics Market, 2016
6.3 Changing Market Shares of Leading Alzheimer’s Diagnostic Markets, 2016-2027
6.4 The Alzheimer’s Diagnostics Market, 2016-2027
6.5 New Criteria and Guidelines to Diagnose Alzheimer’s Disease
6.6 Biomarkers for Alzheimer’s Disease
6.6.1 Leading Companies Pursuing Novel Biomarker Development Strategies
6.7 Alzheimer’s Disease: Advances in Diagnostic Imaging Technologies
6.7.1 Structural Imaging
6.7.2 Functional Imaging
6.7.3 Molecular Imaging Technologies
6.7.3.1 Pittsburgh Compound B (PIB) (GE Healthcare)
6.7.3.2 Florbetapir F18 (18F-AV-45) (Eli Lilly)
6.7.3.3 Flutemetamol (GE Healthcare)
6.7.3.4 Florbetaben (Piramal Imaging)
6.8 Other Alzheimer’s Diagnostics in Development
6.8.1 CSF Proteins
6.8.2 Blood Based Biomarkers for Alzheimer’s Disease
6.8.3 Genetic Risk Profiling
6.8.4 Eye Tests
6.8.5 Nanoparticles
6.9 Leading Companies in the Alzheimer’s Disease Diagnostics Market, 2016
6.9.1 Eli Lilly
6.9.1.1 Recent Performance and Sales Analysis, 2016
6.9.1.2 Alzheimer’s Disease Research Effort
6.9.1.3 Solanezumab
6.9.1.4 Lanabecestat
6.9.1.5 Amyvid (Florbetapir F18)
6.9.1.6 Amyvid Receives Marketing Authorization from the European Commission
6.9.1.7 Flortaucipir F-18
6.9.1.8 LY3002813: Phase I
6.9.2 Amarantus BioScience Holdings, Inc.
6.9.2.1 Recent Performance and Sales Analysis, 2014
6.9.2.2 Avant Diagnostics Inc acquire Amarantus Diagnostics Inc
6.9.2.3 LymPro
6.9.2.4 Intellectual Property Acquisitions
6.9.3 Piramal Enterprises
6.9.3.1 Piramal Imaging SA
6.9.3.2 FDA and EMA Approval of Florbetaben
6.9.3.3 Manufacturing and Distribution Agreements
6.9.4 GE Healthcare
6.9.4.1 GE’s Commitment to Imaging Research in the Alzheimer’s Field
6.9.4.2 Regulatory Approval of Vizamyl - Flutemetamol
6.9.4.3 Licensing Agreements for Flutemetamol
6.9.5 Navidea
6.9.5.1 NAV4694 (Fluorine-18)
6.9.5.2 Collaboration Agreements
6.9.5.3 NAV4694 Clinical Development
6.9.6 DiaGenic
7. The Leading National Markets, 2016-2027
7.1 Regional Breakdown of the Global Alzheimer’s Disease Therapeutics and Diagnostic Market, 2016
7.1.1 The US, Japan and Europe Represent More than 80% of the Total Market
7.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Regional Forecast, 2016-2027
7.3 Changing Market Shares of Leading National Markets 2016-2027
7.4 The US Alzheimer’s Disease Therapeutics and Diagnostics Market, 2016-2027
7.4.1 One in Nine Over the Age of 65 has AD in the US
7.4.2 The US Will Remain the Largest Market Over the Forecast Period
7.5 The European Alzheimer’s Disease Therapeutics and Diagnostics Market, 2016-2027
7.5.1 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.5.2 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.5.3 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.5.4 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.5.5 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.5.6 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.6 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.7 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.8 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.9 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.10 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
7.11 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast, 2016-2027
8. Qualitative Analysis of the Alzheimer’s Disease: Therapeutics and Diagnostics Market, 2016-2027
8.1 SWOT Analysis
8.2 Strengths
8.2.1 Alzheimer’s Disease is a High-Profile Disease
8.2.2 Expanding Patient Population
8.2.3 Strong R&D Pipeline in Both Sectors of the Market
8.3 Weaknesses
8.3.1 Current Drugs Only Treat the Symptoms of Alzheimer’s Disease
8.3.2 Recent Failures of Promising Drug Candidates in Clinical Trials
8.3.3 Poor Macroeconomic Conditions in Key Regions of the Market
8.4. Opportunities
8.4.1 Regulations Seeking Improved Standards of Alzheimer’s Disease Drug Development
8.4.2 Neurodegenerative Diseases Have Strong R&D
8.4.3 Emerging Markets Will Help Drive the Market
8.4.4 Advances in Diagnostic Technologies Will Improve Drug Market Penetration
8.5 Threats
8.5.1 Patent Expiries Will Lead to Further Generic Competition
8.5.2 New AD Therapies Face Political, Commercial and Social Pressures
8.6 Porter’s Five Force Analysis
8.6.1 Rivalry Among Competitors
8.6.2 Threats of New Entrants
8.6.3 Powers of Suppliers
8.6.4 Bargaining Power of Buyers
8.6.5 Threat of Substitutes
9. Research Interviews
9.1 Interview with David Hung, M.D., CEO of Axovant Sciences Inc.
9.1.1 Axovant Sciences Inc
9.1.2 Intepirdine for The Treatment of Alzheimer’s Disease
9.1.3 Intepirdine for The Treatment of Lewy Body Dementia
9.1.4 Candidates in Phase 1 for Alzheimer’s Disease
9.2 Interview with Gill Farrar, PhD, Scientific Director, PET Neurology – Medical Affairs at GE Healthcare
9.2.1 GE Healthcare
9.2.2 Progress in Alzheimer’s Research
9.2.3 Global Alzheimer’s Diagnostics Market
9.2.4 Broadening Vizamyl’s Use
9.2.5 New EMA Guidelines to Include Early Disease Stages
9.3 Interview with Phyllis Ferrell, Vice President and Alzheimer's Disease Global Platform Leader at Eli Lilly and Co.
9.3.1 Eli Lilly and Co.
9.3.2 Global Alzheimer’s Disease Therapeutics market
9.3.3 Eli Lilly’s Pipeline, Drugs and Diagnostics for Alzheimer’s Disease
9.3.4 Amyvid and Challenges in Developing Biomarkers
10. Conclusion
10.1 Novel Diagnostic Technologies Will Emerge First and Then the Disease Modifying Drugs
10.2 Disease Modifying Drugs Will Transform the Declining Alzheimer’s Market
10.3 Demographics Will Help Drive the Market Over the Forecast Period
10.4 Medicines and Diagnostic Tests for Alzheimer’s Disease Hold Great Potential from 2016 to 2027
10.5 Research for Alzheimer’s Happening across the World
Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Leading Sectors in The Neurodegenerative Disease Market, 2016
Table 2.2 Imaging Technologies Used in Alzheimer’s Research, 2017
Table 3.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Shares (%) by Sector, 2016
Table 3.2 Alzheimer’s Disease Therapeutics and Diagnostics Market Forecasts: Revenues ($bn), AGR (%), CAGR (%), 2016-2027
Table 3.3 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Drivers and Restraints, 2016
Table 4.1 The Alzheimer’s Disease Drugs Market: Revenues ($bn) and Market Shares (%) by Leading Drugs, 2016
Table 4.2 Market Shares (%) of the Leading Alzheimer’s Drugs, 2016, 2021, 2027
Table 4.3 The Alzheimer’s Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.4 Namenda: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.5 Aricept: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.6 Exelon: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.7 Alzheimer’s Disease Drugs in the Pipeline Phase 3, 2017
Table 4.8 Disease Drugs in the Pipeline Phase 2, 2017
Table 4.9 Alzheimer’s Disease Drugs in the Pipeline Phase 1 2017
Table 4.10 Solanezumab Clinical Trial Results
Table 4.11 Eli Lilly: Solanezumab Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.12 Roche: Gantenerumab Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.13 Verubecestat Clinical Trial Results
Table 4.14 Merck: Verubecestat MK-8931 Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 4.15 Idalopirdine Clinical Trial Results
Table 5.1 Pfizer: Revenues ($bn) and Revenue Shares (%) by Sector, 2016
Table 5.2 Pfizer: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 5.3 Pfizer: Alzheimer’s Disease Drug Pipeline, 2017
Table 5.4 Eisai: Aricept Regional Sales ($m), AGR (%), 2013
Table 5.5 Eisai: Aricept Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 5.6 Biogen: Alzheimer’s Disease Drugs Pipeline, 2017
Table 5.7 Forest: Namenda’s Historical Revenues ($bn) and AGR (%), 2010-2015
Table 5.8 Allergan: Namenda Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 5.9 Lundbeck: Revenue ($bn) and Revenue Share (%) by Region, 2016
Table 5.10 Ebixa: Revenue ($bn) and Revenue Share (%) by Region, 2016
Table 5.11 Ebixa: Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 5.12 Daiichi Sankyo: Memary Sales Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 5.13 Novartis: Revenue ($bn) and Revenue Shares (%) by Segment, 2016
Table 5.14 vTv Therapeutics: Alzheimer’s Disease Drugs Pipeline, 2016
Table 6.1 The Alzheimer’s Disease Diagnostics Market:Revenues ($bn) and Market Shares (%) by Segment, 2016
Table 6.2 Market Shares (%) of the Leading Alzheimer’s Diagnostics Markets, 2016, 2021 and 2027
Table 6.3 The Alzheimer’s Disease Diagnostics Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Segment, 2016-2027
Table 6.4 Key Alzheimer’s Diagnostic Tests in Development, 2017
Table 6.5 Eli Lilly Pipeline Including Drugs and Diagnostics for Alzheimer’s Disease
Table 6.6 DiaGenic: Alzheimer’s Disease Diagnostics Pipeline, 2016
Table 7.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) and Market Share (%) by Region, 2016
Table 7.2 The Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Region, 2016-2027
Table 7.3 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast CAGR (%), 2016-2021, 2021-2027, 2016-2027
Table 7.4 Market Shares (%) of the Leading Regional Alzheimer’s Disease Therapeutics and Diagnostics Markets, 2016, 2021 and 2027
Table 7.5 The US Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.6 The European Alzheimer’s Therapeutics and Diagnostics Market: Revenue ($bn), European Market Share (%) and Global Market Share (%) by Leading Countries, 2016
Table 7.7 The European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.8 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.9 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR(%), 2016-2027
Table 7.10 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR(%), 2016-2027
Table 7.11 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.12 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.13 The Rest of Europe Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.14 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.15 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.16 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.17 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.18 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast:
Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 7.19 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market
Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
Table 8.1 SWOT Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2016
Table 10.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2016, 2021 and 2027 and CAGR (%) 2016-2021 and 2021-2027 by Region
Table 10.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market ($bn) by Sector, 2016, 2021 and 2027
List of Figures
Figure 1.1 Alzheimer’s Disease Therapeutics and Diagnostics:Overview of Submarkets and Segments
Figure 3.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Sector, 2016
Figure 3.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Market Share (%) by Sector, 2016
Figure 3.3 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 3.4 Current Stage in Research and Development for Alzheimer’s Disease
Figure 4.1 The Alzheimer’s Disease Drugs Market: Revenues ($bn) by Leading Drugs, 2016
Figure 4.2 The Alzheimer’s Disease Drugs Market: Market Shares (%) by Leading Drugs, 2016
Figure 4.3 The Alzheimer’s Therapeutics Market: Market Shares (%) by Drug, 2021
Figure 4.4 The Alzheimer’s Therapeutics Market: Market Shares (%) by Drug, 2027
Figure 4.5 The Alzheimer’s Disease Drugs Market Forecast: Revenue ($bn), 2016-2027
Figure 4.6 Namenda: Sales Forecast ($bn), 2016-2027
Figure 4.7 Aricept: Sales Forecast ($bn), 2016-2027
Figure 4.8 Exelon: Sales Forecast ($bn), 2016-2027
Figure 4.9 Eli Lilly: Solanezumab Sales Forecast ($bn), 2016-2027
Figure 4.10 Roche: Gantenerumab Sales Forecast ($bn), 2016-2027
Figure 4.11 Merck: MK-8931 Sales Forecast ($bn), 2016-2027
Figure 5.1 Pfizer: Historical Revenues ($bn), 2012-2016
Figure 5.2 Pfizer: Revenues ($bn) by Sector, 2016
Figure 5.3 Pfizer: Revenue Shares (%) by Sector, 2016
Figure 5.4 Pfizer: Aricept Sales Forecast ($bn), 2016-2027
Figure 5.5 Pfizer: Historical R&D Expenditure ($bn), 2012-2016
Figure 5.6 Eisai: Aricept Historical Revenue ($bn) 2013-2016
Figure 5.7 Eisai: Aricept Sales Forecast ($bn), 2016-2027
Figure 5.8 Eisai: Historical R&D Expenditure ($bn), 2013-2015
Figure 5.9 Forest: Namenda’s Historical Revenue ($bn), 2010-2015
Figure 5.10 Allergan: Namenda Sales Forecast ($bn), 2016-2027
Figure 5.11 Lundbeck: Revenue Share (%) by Region, 2016
Figure 5.12 Lundbeck: Revenue Share ($bn) by Region, 2016
Figure 5.13 Lundbeck: R&D Expenditure ($bn), 2015-2016
Figure 5.14 Ebixa: Revenue ($bn) by Region, 2016
Figure 5.15 Ebixa: Revenue Shares (%) by Region, 2016
Figure 5.16 Ebixa: Sales Forecast ($bn), 2016-2027
Figure 5.17 Daiichi Sankyo: Historical Revenue ($bn), 2012-2015
Figure 5.18 Daiichi Sankyo: Memary Historical Revenue ($bn), 2013-2015
Figure 5.19 Daiichi Sankyo: Memary Sales Forecast ($bn), 2016-2027
Figure 5.20 Novartis: Historical Revenues ($bn), 2012-2016
Figure 5.21 Novartis: Revenues ($bn) by Segment, 2016
Figure 5.22 Novartis: Revenue Shares (%) by Segment, 2016
Figure 5.23 Exelon: Historical Revenue Shares (%) by Region, 2016
Figure 6.1 The Alzheimer’s Disease Diagnostics Market: Revenues ($bn) by Segment, 2016
Figure 6.2 The Alzheimer’s Disease Diagnostics Market: Market Shares (%) by Segment, 2016
Figure 6.3 The Alzheimer’s Diagnostics Market: Market Share (%) by Segment, 2021
Figure 6.4 The Alzheimer’s Diagnostics Market: Market Share (%) by Segment, 2027
Figure 6.5 The Alzheimer’s Disease Diagnostics Market Forecast: Revenues ($bn), 2016-2027
Figure 6.6 Eli Lilly: Historical Revenue ($bn), 2012-2016 2012-2016
Figure 6.7 AmarantusBioScience: R&D Costs ($m), 2014-2015
Figure 6.8 Piramal Enterprise Historical Revenue by Business Unit 2015-2016
Figure 6.9 GE Healthcare Historical Revenues ($bn) 2014-2016
Figure 7.1 The Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) by Region, 2016
Figure 7.2 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2016-2021
Figure 7.3 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2021-2026
Figure 7.4 Regional Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: CAGR (%), 2016-2027
Figure 7.5 The Alzheimer’s Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2021
Figure 7.6 The Alzheimer’s Therapeutics and Diagnostics Market: Market Shares (%) by Region, 2027
Figure 7.7 The US Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.8 The US Demographics: No. of People Aged 65 or Over, 2015 and 2030 Forecast
Figure 7.9 The European Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenue ($bn) by Leading Countries, 2016
Figure 7.10 The European Alzheimer’s Disease Therapeutics and Diagnostics Market: Market Shares (%) by Leading Countries, 2016
Figure 7.11 The European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.12 The German Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.13 The French Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.14 The UK Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.15 The Italian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.16 The Spanish Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.17 The Other European Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.18 The Japanese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.19 The Chinese Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.20 China’s Historical Healthcare Expenditure ($bn), 2001-2010
Figure 7.21 The Indian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.22 The Brazilian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.23 The Russian Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 7.24 The Rest of the World Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast: Revenue ($bn), 2016-2027
Figure 8.1 The Global Over 65 Population: Forecast (millions), 2010-2050
Figure 8.2 Porter’s Five Force Analysis of the Alzheimer’s Disease Therapeutics and Diagnostics Market, 2016
Figure 10.1 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Revenues ($bn) in 2016, 2021 and 2027
Figure 10.2 The Global Alzheimer’s Disease Therapeutics and Diagnostics Market ($bn) by Segment, 2016, 2021 and 2027
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
